This article regarding diabetes will go into…
Before you continue… You really need to read this if you have diabetes. CLICK HERE now.(will open in new window)
Freely download and read the article (mentioned in the title of this post) Right HERE along with dozens of other articles on diabetes.
NovaBay Pharmaceuticals, Inc. (NYSE Amex : NBY), a scientific stage biotechnology corporate creating its first-in-class, anti-infective Aganocide(R) compounds for the native non-systemic treatment and prevention of antibiotic-resistant infections, today has provided an on-demand webcast show from its Manager, Dr . Ron Najafi. The audio and slide display, recently presented at the Roth Capital Partners 23rd Yearly Expansion Stock Meeting, is to be had at : the internet website press unlock distributors The display should be available for 90 days. . About NovaBay Pharmaceuticals, Incorporated.
NovaBay prescribed drugs is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, manmade anti-infectives with activity against bacteria, fungi and viruses, and are being developed to deal with and stop a good range of local, non-systemic diseases with a low chance of developing bacterial resistance. NovaBay is focusing its era on 4 distinct therapeutic areas : dermatology, ophthalmology, urology and health center illnesses. In dermatology, the center of attention is on developing NVC-422 gel for impetigo and acne.
NovaBay has a benefit of being partnered with Galderma, the leading dermatology company in the world . In ophthalmology, the goal is to increase an eye drop for conjunctivitis with Alcon, the planet's foremost ophthalmology company. In urology, NovaBay wants to reduce the occurrence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract diseases with an irrigation answer containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing injuries,eg pressure, venous stasis and diabetic ulcers with its exclusive antimicrobial solution, NeutroPhaseTM, which has received 2 510K clearances from the Food and Drug Administration. For further info, visit novabaypharma.